Search
Mersalyl
go.drugbank.com/drugs/DB09338ExperimentalInterestingly, it has been found to have antiviral properties in mice [L1584]. … The sodium salt of a mercury-containing derivative of salicylamide, was formerly used (often in combination with theophylline) to treat edema, due to its powerful diuretic properties [L1577].
Colesevelam
go.drugbank.com/drugs/DB00930ApprovedInvestigationalColesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. … It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.
Setmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. … [L24474] It is an agonist of the melanocortin 4 receptor.
Categories: Melanocortin 4 Receptor Agonist, Melanocortin 4 Receptor AgonistsDroloxifene
go.drugbank.com/drugs/DB15641ExperimentalIts higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity … It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required.
Categories: Compounds used in a research, industrial, or household settingBenzphetamine
go.drugbank.com/drugs/DB00865ApprovedIllicitA sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Synonyms: d-N-methyl-N-benzyl-β-phenylisopropylamine, (+)-N-benzyl-N,α-dimethylphenethylamineCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesAcoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigationalAcoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. … [L51958] Similar to the previously developed [tafamidis], acoramidis is used to stabilize TTR in its tetrameric form, preventing the formation of amyloidogenic monomers and the progression of amyloidosis
Synonyms: 3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acidCategories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 CYP2C9 InhibitorsRilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune
Synonyms: (3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-?-[2-methyl-2-[4-(3-oxetanyl)-1-piperazinyl]propylidene]-?-oxo-1-piperidinepropanenitrile, (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrileCategories: P-glycoprotein inhibitors, P-glycoprotein substratesMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalMaraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the … It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
Categories: CCR5 Co-receptor Antagonist, Cytochrome P-450 SubstratesProducts: CELSENTRI® 150 MG, CELSENTRI® 300 MGDabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigational[L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955] … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic IndexProducts: TAFINLAR®75 MG CÁPSULAS DURAS, TAFINLAR® 50 MG CÁPSULAS DURASNirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … [L44146] It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry process, and neutralizes several RSV A and B strains.
Synonyms: Immunoglobulin g1-kappa, anti-(human respiratory syncytial virus fusion glycoprotein f0 (protein f))human monoclonal antibody.gamma.1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4, *01 (90.1%)) (8.8.19) (1-126) -homo sapiens ighg1*03Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody